Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rossanna Di Maio is active.

Publication


Featured researches published by Rossanna Di Maio.


European Journal of Medicinal Chemistry | 2000

Synthesis and antitrypanosomal evaluation of E-isomers of 5-nitro-2-furaldehyde and 5-nitrothiophene-2-carboxaldehyde semicarbazone derivatives. Structure-activity relationships.

Hugo Cerecetto; Rossanna Di Maio; Mercedes González; Mariela Risso; Gabriel Sagrera; Gustavo Seoane; Ana Denicola; Gonzalo Peluffo; Celia Quijano; A.O.M. Stoppani; Margot Paulino; Claudio Olea-Azar; Miguel Angel Basombrío

Several novel semicarbazone derivatives were prepared from 5-nitro-2-furaldehyde or 5-nitrothiophene-2-carboxaldehyde and semicarbazides bearing a spermidine-mimetic moiety. All derivatives presented the E-configuration, as determined by NMR-NOE experiments. These compounds were tested in vitro as potential antitrypanosomal agents, and some of them, together with the parent compounds, 5-nitro-2-furaldehyde and 5-nitrothiophene-2-carboxaldehyde semicarbazone derivatives, were also evaluated in vivo using infected mice. Structure-activity relationship studies were carried out using voltammetric response and lipophilic-hydrophilic balance as parameters. Two of the compounds (1 and 3) displayed the highest in vivo activity. A correlation was found between lipophilic-hydrophilic properties and trypanocidal activity, high R(M) values being associated with low in vivo effects.


Farmaco | 1998

Synthesis and anti-trypanosomal activity of novel 5-nitro-2-furaldehyde and 5-nitrothiophene-2-carboxaldehyde semicarbazone derivatives

Hugo Cerecetto; Rossanna Di Maio; Gerardo Ibarruri; Gustavo Seoane; Ana Denicola; Gonzalo Peluffo; Celia Quijano; Margot Paulino

Several novel semicarbazones derivatives were prepared from 5-nitro-2-furaldehyde or 5-nitrothiophene-2-carboxaldehyde, and tested in vitro as potential anti-trypanosomal agents. The compounds were prepared in good to excellent yields in 2-3 steps from readily available starting materials. Some derivatives were found to be active against Trypanosoma cruzi with an activity similar to that of Nifurtimox.


Archiv Der Pharmazie | 2002

Benzo[1,2-c]1,2,5-oxadiazole N-oxide derivatives as potential antitrypanosomal drugs. Structure-activity relationships. Part II.

Gabriela Aguirre; Hugo Cerecetto; Rossanna Di Maio; Mercedes González; Williams Porcal; Gustavo Seoane; Miguel Ángel Ortega; Ignacio Aldana; Antonio Monge; Ana Denicola

The preparation of new derivatives of benzo[1, 2‐c]1, 2, 5‐oxadiazole N‐oxide is described. These derivatives were chosen in order to investigate and confirmprevious structural features found necessary to display an adequate antitrypanosomal activity. The compounds synthesized were tested in vitro against epimastigote forms of Trypanosoma cruzi.The presence of a bromine atom in the benzo system produced compounds less active than the corresponding de‐halo analogues. However, 5‐(bromomethyl)‐7‐bromobenzo[1, 2‐c]oxadiazole N‐oxide (23) was the most cytotoxic compound against T. cruzi. For this, the 50% inhibitory dose (ID50) was determined, it was of the same order as that of Nifurtimox. From statistical analysis we could establish a relationship between lipophilic‐hydrophilic balance of the derivatives with their effectiveness as antichagasic compounds.


Letters in Drug Design & Discovery | 2005

Novel Benzo[1,2-c]1,2,5-Oxadiazole N-Oxide Derivatives as Antichagasic Agents: Chemical and Biological Studies

Claudio Olea-Azar; Carolina Rigol; Fernando Mendizabal; Hugo Cerecetto; Rossanna Di Maio; Mercedes González; Williams Porcal; Antonio Morello; Yolanda Repetto; Juan Diego Maya

This research was supported by FONDECYT 1000834, 7040037, 1020095, CSIC (UdelaR), CLEMENTE ESTABLE and TWAS grants. We thank a scholarship for C. Rigol from RELACQ.


European Journal of Medicinal Chemistry | 2010

Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity

Guzmán Álvarez; Beatriz Aguirre-López; Javier Varela; Mauricio Cabrera; Alicia Merlino; Gloria V. López; María Laura Lavaggi; Williams Porcal; Rossanna Di Maio; Mercedes González; Hugo Cerecetto; Nallely Cabrera; Ruy Pérez-Montfort; Marieta Tuena de Gómez-Puyou; Armando Gómez-Puyou

Triosephosphate isomerase from Trypanosoma cruzi (TcTIM), an enzyme in the glycolytic pathway that exhibits high catalytic rates of glyceraldehyde-3-phosphate- and dihydroxyacetone-phosphate-isomerization only in its dimeric form, was screened against an in-house chemical library containing nearly 230 compounds belonging to different chemotypes. After secondary screening, twenty-six compounds from eight different chemotypes were identified as screening positives. Four compounds displayed selectivity for TcTIM over TIM from Homo sapiens and, concomitantly, in vitro activity against T. cruzi.


European Journal of Medicinal Chemistry | 2013

Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents

Elsa Moreno-Viguri; Silvia Galiano; Goutham Devarapally; Philip W. Crawford; Amaia Azqueta; Leire Arbillaga; Javier Varela; Estefanía Birriel; Rossanna Di Maio; Hugo Cerecetto; Mercedes González; Ignacio Aldana; Antonio Monge; Silvia Pérez-Silanes

As a continuation of our research and with the aim of obtaining new agents against Chagas disease, an extremely neglected disease which threatens 100 million people, eighteen new quinoxaline 1,4-di-N-oxide derivatives have been synthesized following the Beirut reaction. The synthesis of the new derivatives was optimized through the use of a new and more efficient microwave-assisted organic synthetic method. The new derivatives showed excellent in vitro biological activity against Trypanosoma cruzi. Compound 17, which was substituted with fluoro groups at the 6- and 7-positions of the quinoxaline ring, was the most active and selective in the cytotoxicity assay. The electrochemical study showed that the most active compounds, which were substituted by electron-withdrawing groups, possessed a greater ease of reduction of the N-oxide groups.


Journal of Molecular Structure-theochem | 2002

Computer assisted design of potentially active anti-trypanosomal compounds

Margot Paulino; Fredricio Iribarne; María Hansz; Mauricio Vega; Gustavo Seoane; Hugo Cerecetto; Rossanna Di Maio; Ignez Caracelli; Julio Zukerman-Schpector; Claudio Olea; A.O.M. Stoppani; Mathew Berriman; Alan H. Fairlamb; O. Tapia

Abstract A computer assisted molecular modeling was used to design molecules having a shape complementary to the active site of glutathione reductase (GR) and trypanothione reductase (TR). The designed 5-nitro compound derivatives, were obtained from structural knowledge gleaned on glutathione (GSSG), trypanothione (T[S]2) and GSP disulfide (glutathionylspermidine disulfide). These molecules form complexes with the enzymes GR and TR. The theoretical lead compound was: N1-[1-(5-nitro-2-furyl)methylidene]-N4-{4-[3-(2,2,2-trifluoroacetyl)hexahydro-1-1-pyrimidynil]butyl} semicarbazide (NPIPCO). A multi-disciplinary team developed around the efforts to synthesize this lead. In this work we report on eight compounds that were synthesized in the pathway to NPIPCO: 4-(2-methoxyethyl)-1-, 4-butyl-1-, 4-hexyl-1- and 2-methoxphenyl-1-(5-nitrofurfurilidene) semicarbazides and the corresponding 5-nitrothiophenes. These substances are expected to act as pro-transition state analogues. Enzymologic studies proved that many of these compounds are inhibitors of TR. Furthermore, they showed inhibitory activity on Tripanosoma cruzi growth in vitro.


Antimicrobial Agents and Chemotherapy | 2013

Evaluating 5-nitrofurans as trypanocidal agents

Christopher Bot; Belinda S. Hall; Guzmán Álvarez; Rossanna Di Maio; Mercedes González; Hugo Cerecetto; Shane R. Wilkinson

ABSTRACT The nitroheterocycle nifurtimox, as part of a nifurtimox-eflornithine combination therapy, represents one of a limited number of treatments targeting Trypanosoma brucei, the causative agent of human African trypanosomiasis. The mode of action of this prodrug involves an initial activation reaction catalyzed by a type I nitroreductase (NTR), an enzyme found predominantly in prokaryotes, leading to the formation of a cytotoxic unsaturated open-chain nitrile metabolite. Here, we evaluate the trypanocidal activities of a library of other 5-nitrofurans against the bloodstream form of T. brucei as a preliminary step in the identification of additional nitroaromatic compounds that can potentially partner with eflornithine. Biochemical screening against the purified enzyme revealed that all 5-nitrofurans were effective substrates for T. brucei NTR (TbNTR), with the preferred compounds having apparent kcat/Km values approximately 50-fold greater than those of nifurtimox. For several compounds, in vitro reduction by this nitroreductase yielded products characterized by mass spectrometry as either unsaturated or saturated open-chain nitriles. When tested against the bloodstream form of T. brucei, many of the derivatives displayed significant growth-inhibitory properties, with the most potent compounds generating 50% inhibitory concentrations (IC50s) around 200 nM. The antiparasitic activities of the most potent agents were demonstrated to be NTR dependent, as parasites having reduced levels of the enzyme displayed resistance to the compounds, while parasites overexpressing TbNTR showed hypersensitivity. We conclude that other members of the 5-nitrofuran class of nitroheterocycles have the potential to treat human African trypanosomiasis, perhaps as an alternative partner prodrug to nifurtimox, in the next generation of eflornithine-based combinational therapies.


Current Topics in Medicinal Chemistry | 2014

Mutagenicity of N-oxide Containing Heterocycles and Related Compounds: Experimental and Theoretical Studies

Martín Gabay; Mauricio Cabrera; Rossanna Di Maio; Juan A. Páez; Nuria E. Campillo; María Laura Lavaggi; Hugo Cerecetto; Mercedes González

In the development of new drugs, it is very important to know the effects these may bring to those who consume them. Drugs which act upon certain diseases must not cause toxic side effects on healthy organs. These toxic side effects can be quite varied, i.e. mutagenicity, clastogenicity, teratogenicity, etc., but undoubtedly the mutagenicity officiate in the selection process, during preclinical testing, to advance in clinical trials. Mutagenic compounds are removed and cannot continue its development. There are preclinical studies of mutagenicity and genotoxicity, ranging from in vitro to in vivo studies. Particularly, Ames test is recommended by ICH as the first input in these studies. Herein, we investigated the mutagenicity of an in-house chemical library of eighty five N-oxide containing heterocycles using Ames test in Salmonella thyphimurium TA 98 with and without S9 activation and the use of neural networks in order to predict this nondesired activity. N-oxide containing heterocycles are especially relevant regarding its pharmacological activities as antitrypanosoma, anti-leishmania, anti-tuberculosis, anti-cancer, chemopreventive, anti-inflammatory, anti-atherogenic, and analgesic agents. In some cases, a relationship was found between the presence of N-oxide and mutagenicity. Specifically, benzofuroxan system seems to be responsible for the mutagenicity of certain agents against Chagas disease and certain anti-inflammatory agents. However other N-oxides, such as furoxans with anti-inflammatory and anti-atherosclerosis activities, seem to lack mutagenicity. In other cases, such as quinoxaline dioxides with anti-parasitic activity, mutagenicity shows to be substituent dependent. Applying CODES neural network two models were defined, one without metabolism and other with metabolism. These models predict the mutagenicity with and without metabolism in an excellent manner.


Bioorganic & Medicinal Chemistry Letters | 2004

Quinoxaline N,N'-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity relationships.

Gabriela Aguirre; Hugo Cerecetto; Rossanna Di Maio; Mercedes González; Marı́a Elena Montoya Alfaro; Andrés Jaso; Belén Zarranz; Miguel Ángel Ortega; Ignacio Aldana; Antonio Monge-Vega

Collaboration


Dive into the Rossanna Di Maio's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gabriela Aguirre

University of the Republic

View shared research outputs
Top Co-Authors

Avatar

Ana Denicola

University of the Republic

View shared research outputs
Top Co-Authors

Avatar

Williams Porcal

University of the Republic

View shared research outputs
Top Co-Authors

Avatar

Lucía Boiani

University of the Republic

View shared research outputs
Top Co-Authors

Avatar

Gustavo Seoane

University of the Republic

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eliana Cabrera

University of the Republic

View shared research outputs
Researchain Logo
Decentralizing Knowledge